Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
 |
|
as soon as is submitted to ZB.
Early detection at different stages of type 1 diabetes.
Diabetes Stoffwechs. Herz 33:74 (2024)
Type 1 diabetes can be identified years before clinical diagnosis based on the detection of multiple islet autoantibodies. Based on this and depending on glycaemic status, a distinction is made between the pre-symptomatic stages 1 and 2. In scientific studies, early detection was associated with significant health benefits at the time of diagnosis and beyond. Teplizumab, an anti-CD3 monoclonal antibody, is the first drug available in the US that has been shown to delay the onset of diabetes in stage 2 by more than 2.5 years. It may soon be available in Europe. This perspective is fuelling the debate about extending population-based screening, but it also requires ethical considerations and a clear public health framework for the medical and psychological care of those affected.
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Type 1 Diabetes; Screening; Autoantibodies; Teplizumab; Immunotherapy; Beta-cell Function; B-lymphocyte Depletion; Double-blind; New-onset; Islet Autoantibodies; Children; Risk; Ketoacidosis; Disease; Relatives
ISSN (print) / ISBN
1861-7603
Journal
Diabetes, Stoffwechsel und Herz
Quellenangaben
Volume: 33,
Issue: 5,
Article Number: 74
Publisher
Verl. Kirchheim und Co.
Publishing Place
Postfach 25 24, Mainz, 55015, Germany
Non-patent literature
Publications
Reviewing status
Peer reviewed